<DOC>
	<DOC>NCT01830010</DOC>
	<brief_summary>Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies</brief_summary>
	<brief_title>A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Patients aged 18 to 65 years, inclusive Patients must have a hematological malignancy that as per standard medical practice requires myeloablative conditioning (including short term myeloablative reduced intensity conditioning) followed by allogeneic hematopoetic stem cell transplant Karnofsky Performance status â‰¥60%. Suitable stem cell source available according to the graft selection algorithm using Tcell replete peripheral stem cells as a graft source Resting heart rate below 55 Significant cardiac disease (such as arrhytmia, heart failure) or any significant condition which in the investigators opinion would make the patient ineligible Previous allogeneic HSCT Any drug required that is not compatible with KRP203 (e.g. betablockers or antithymocyte globulin)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>